Galapagos NV: Galapagos to showcase CAR-T point-of-care manufacturing and initial Phase 1/2 CLL data with CD19 CAR-T candidate, GLPG5201, at the EHA 2023 congress

All 7 out of 7 eligible patients with relapsed/refractory chronic lymphocytic leukemia (rrCLL), with or without Richter's Transformation (RT), responded to treatment (Objective Response Rate of 100%)1

Related Keywords

Mechelen ,Region Flamande ,Belgium ,Zeiten ,Mecklenburg Vorpommern ,Germany ,Japan ,Daniel Estban ,Sergi Betriu ,Jeevan Shetty ,Marieke Vermeersch ,Sandra Cauwenberghs ,Nuria Martinez Cibrian ,Van Gijsel ,Julio Delgado ,Christian Jacques ,Mercedes Montoro ,Stefan Klotter ,Valentin Ortiz Maldonado ,Leticia Alserawan ,Margotj Pont ,Head Of Clinical Development Oncology At Galapagos ,Exchange Commission ,European Hematology Association ,Twitter ,Objective Response Rate ,Clinical Development Oncology ,Clinical Results ,Maike Spoon ,Bayesian Optimal Interval ,Cancer Journal ,Stabile Ertr ,Chart Profi Stefan Klotter ,Blue Chips ,Galapagos ,Showcase ,Joint ,Mare ,Manufacturing ,Nitial ,Hase ,Data ,Cvd19 ,Candidate ,Lpg5201 ,023 ,Congress ,